...
首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Subcoating with Kollidon VA 64 as water barrier in a new combined native dextran/HPMC-cetyl alcohol controlled release tablet.
【24h】

Subcoating with Kollidon VA 64 as water barrier in a new combined native dextran/HPMC-cetyl alcohol controlled release tablet.

机译:在新型的天然葡聚糖/ HPMC-鲸蜡醇控释片组合中,以Kollidon VA 64作为阻水剂进行底涂。

获取原文
获取原文并翻译 | 示例
           

摘要

A novel oral controlled delivery system for propranolol hydrochloride (PPL) was developed and optimized using wet granulation process. We are studying the ability of subcoating with Kollidon VA 64 as a barrier to water penetration in matrix cores combined hydrophilic (native dextran-HPMC)/hydrophobic (cetyl alcohol) prior to film coating with Opradry II-YS-30-18056. The copovidone (i.e., Kollidon VA 64) not only increases the mechanical properties of tablets (less friability) but also reduces the amount of absorbed water from the air in tropical stability condition (25 degrees C and 75% relative humidity). The in vitro dissolution profiles of coated sustained-release matrix tablets of racemic PPL were determined and compared with uncoated tablet cores according to the United States Pharmacopeia (USP) Tolerance Specifications for Propranolol Hydrochloride Extended-Release Capsules. A comparative kinetic study of the present matrix tablets (coated and uncoated cores) and commercial SUMIAL RETARD capsules(reference formulation (R) (Spain) was established). The values for the similarity factor (f(2)=61.756, f(2)=72.326 and f(2)=88.509 for initial time, one year and two years, respectively (uncoated cores vs. capsule) and f(2)=63.904, f(2)=69.502 and f(2)=76.348 (coated tablets vs. capsule) for initial time, one year and 2 two years, respectively) suggested that the dissolution profiles of the present three sustained-release oral dosage forms are similar and stable during two years under stability condition.
机译:使用湿法制粒工艺开发并优化了盐酸普萘洛尔的新型口服控释系统。我们正在研究在使用Opradry II-YS-30-18056涂膜之前,将亲水性(天然葡聚糖-HPMC)/疏水性(鲸蜡醇)与亲水性(天然葡聚糖-HPMC)/疏水性(鲸蜡醇)结合使用Kollidon VA 64底涂层的能力,以防止水渗透到基质芯中。共聚维酮(即Kollidon VA 64)不仅增加了片剂的机械性能(降低了脆性),而且还减少了在热带稳定条件下(25摄氏度和75%相对湿度)从空气中吸收的水量。根据美国药典(USP)盐酸普萘洛尔缓释胶囊的耐受性规格确定外消旋PPL的包衣缓释基质片剂的体外溶出度,并将其与未包衣片剂核进行比较。建立了本基质片剂(包衣和未包衣的药芯)和市售SUMIAL RETARD胶囊(参考配方(R)(西班牙))的对比动力学研究。相似系数的值(f(2)= 61.756,f(2)= 72.326和f(2)= 88.509分别为初始时间,一年和两年(未涂层芯与胶囊)和f(2)分别为初始时间,一年和两年(分别为= 63.904,f(2)= 69.502和f(2)= 76.348(包衣片剂与胶囊剂))表明,目前三种缓释口服剂量的溶出度在稳定条件下的两年内,它们的形式相似且稳定。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号